- Home
- NYC vs PSTV Comparison
NYC vs PSTV Comparison
Compare NYC & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYC | PSTV |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 27.9M |
| IPO Year | 2014 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NYC | PSTV |
|---|---|---|
| Price | $8.11 | $4.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $55.00 |
| AVG Volume (30 Days) | 870.0 | ★ 4.3M |
| Earning Date | 05-08-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,213,000.00 |
| Revenue This Year | $8.40 | $21.93 |
| Revenue Next Year | $1.62 | $279.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.03 | $0.13 |
| 52 Week High | $16.30 | $4.10 |
Technical Indicators
Market Signals| Indicator | NYC | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 87.89 |
| Support Level | $7.12 | $0.37 |
| Resistance Level | $8.28 | N/A |
| Average True Range (ATR) | 0.30 | 0.31 |
| MACD | -0.01 | 0.45 |
| Stochastic Oscillator | 9.18 | 91.76 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).